Evercore ISI analyst Joshua Schimmer maintained a Buy rating on Trillium Therapeutics (TRIL – Research Report) on April 30 and set a price target of $28.00. The company’s shares closed last Friday at $9.51.
According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 15.2% and a 53.1% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Finch Therapeutics Group, BioMarin Pharmaceutical, and Viracta Therapeutics.
Currently, the analyst consensus on Trillium Therapeutics is a Strong Buy with an average price target of $24.00, which is a 169.1% upside from current levels. In a report issued on April 26, JonesTrading also reiterated a Buy rating on the stock with a $25.00 price target.
The company has a one-year high of $20.96 and a one-year low of $4.62. Currently, Trillium Therapeutics has an average volume of 1.39M.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TRIL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.